NANOVIRICIDES, INC.
Current- President, Chairman of the Board of Directors Current · dates not published
Skip to record
Executive record
Alpha ID: alpha:person:anil-diwanVersion: public-0As of: 2026-09-30
Not yet claimed10 published Claims3 sources
- Executive
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Founder, President and Chairman of NanoViricides. Also serves as CEO and Director of TheraCour Pharma, Inc., owning approximately 90% of its capital stock. Holds employment agreement with annual base salary of $400,000.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Executive career
- Current · dates not publishedPresident and Chief Executive Officer · NANOVIRICIDES, INC.
- 2025 to end not publishedExecutive title: President and Executive Chairman of the Board of Directors · Organization not publishedNNVC 10-K executive officers
- Dates not publishedExecutive title: President and Chief Executive Officer · Organization not published
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
Open source
sec def 14a · Source published: Oct 8, 2025 · Retrieved: Sep 12, 2026
Supports 3 claims
- Professional Role: President and Chief Executive Officer at NANOVIRICIDES, INC. · Claim reviewed: Sep 12, 2026
- Professional Role: President, Chairman of the Board of Directors at NANOVIRICIDES, INC. · Claim reviewed: Sep 12, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: Sep 12, 2026
NNVC 10-K executive officers
sec filing · Source published: Sep 29, 2025 · Retrieved: May 16, 2026
Supports 6 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at NANOVIRICIDES, INC. · Claim reviewed: May 16, 2026
- Executive title: Executive title: President and Executive Chairman of the Board of Directors · Claim reviewed: May 16, 2026
- Other Company Role: Anil Diwan is also linked to TheraCour Pharma, Inc. as CEO and Director. · Claim reviewed: May 16, 2026
- Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of NANOVIRICIDES, INC. · Claim reviewed: Sep 12, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-30
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope